These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33811492)

  • 1. Are adverse drug reactions to anti-diabetic drugs more common in patients whose treatment do not adhere to diabetes management clinical guidelines? Comments on a study report.
    Rezaie Z; Taghizadeh-Ghehi M; Jafarzadeh Kohneloo A
    Eur J Clin Pharmacol; 2021 Sep; 77(9):1429-1430. PubMed ID: 33811492
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse drug reactions to anti-diabetic drugs are commonest in patients whose treatment do not adhere to diabetes management clinical guidelines: cross-sectional study in a tertiary care service in sub-Saharan Africa.
    Elangwe A; Katte JC; Tchapmi D; Figueras A; Mbanya JC
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1601-1605. PubMed ID: 32607780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatotoxicity due to commonly-used drugs].
    García-Cortés M; Andrade RJ; Lucena MI; González-Grande R; Camargo R; Fernández-Bonilla E; Martos JV; Alcántara R
    Gastroenterol Hepatol; 2005 Oct; 28(8):461-72. PubMed ID: 16185582
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies.
    Liu D; Chen H; Song F; Ahmed MA; Wu H
    Adv Ther; 2020 Oct; 37(10):4356-4369. PubMed ID: 32845473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Momordica Charantia (Karela/bitterguord) in Type 2 Diabetic Patients Taking Allopathic Drugs: A pilot study.
    Rauniyar GP; Sinha R; Chapagain K; Maskey R; Pandey DR
    Kathmandu Univ Med J (KUMJ); 2021; 19(74):143-147. PubMed ID: 34819444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug-induced hepatitis. Local monitoring criteria].
    Rossini L; Leone L
    Minerva Med; 1980 Nov; 71(47):3455-61. PubMed ID: 6161323
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes.
    van Roozendaal BW; Krass I
    Pharm World Sci; 2009 Oct; 31(5):580-595. PubMed ID: 19626455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to anti-diabetic drugs among patients with Type 2 diabetes mellitus at Muhimbili National Hospital, Dar es Salaam, Tanzania- A cross-sectional study.
    Rwegerera GM
    Pan Afr Med J; 2014; 17():252. PubMed ID: 25309652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions.
    Stern MP
    Diabetes Care; 1999 May; 22(5):844-5. PubMed ID: 10332692
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks.
    Eurich DT; Majumdar SR; McAlister FA; Tsuyuki RT; Johnson JA
    Open Med; 2011; 5(1):e33-4. PubMed ID: 22046218
    [No Abstract]   [Full Text] [Related]  

  • 11. [Reactions and interactions of drugs. Safety measures from Drug Safety Committee of the United Kingdom].
    D'Arcy PF
    J Pharm Belg; 1999; 54(2):44-7. PubMed ID: 10380410
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment of drug related problems among type 2 diabetes mellitus patients with hypertension in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia.
    Ayele Y; Melaku K; Dechasa M; Ayalew MB; Horsa BA
    BMC Res Notes; 2018 Oct; 11(1):728. PubMed ID: 30314443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
    Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
    N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
    [No Abstract]   [Full Text] [Related]  

  • 14. Positioning newer drugs in the management of type 2 diabetes.
    Marx N; Davies MJ; Grant PJ; Mathieu C; Petrie JR; Cosentino F; Buse JB
    Lancet Diabetes Endocrinol; 2021 Mar; 9(3):139-140. PubMed ID: 33607039
    [No Abstract]   [Full Text] [Related]  

  • 15. Positioning newer drugs in the management of type 2 diabetes.
    Prattichizzo F; Ceriello A
    Lancet Diabetes Endocrinol; 2021 Mar; 9(3):138-139. PubMed ID: 33607038
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Incidence of Antihypertensive Drug-induced Side Effects in Patients with Diabetes Mellitus Type 2 and Hypertension.
    Loga-Zec S; Asceric M; Loga-Andrijic N; Kapetanovic B; Zerem E
    Med Arch; 2014 Dec; 68(6):372-5. PubMed ID: 25648509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative Management of Glucose-lowering Drugs: Comment.
    Gregory SH
    Anesthesiology; 2021 Feb; 134(2):349. PubMed ID: 33433618
    [No Abstract]   [Full Text] [Related]  

  • 19. Perioperative Management of Glucose-lowering Drugs: Comment.
    Thiruvenkatarajan V; Jesudason D; Nanjappa N; Meyer EJ; Van Wijk RM
    Anesthesiology; 2021 Feb; 134(2):349-350. PubMed ID: 33433615
    [No Abstract]   [Full Text] [Related]  

  • 20. Perioperative Management of Glucose-lowering Drugs: Reply.
    Preiser JC; Cnop M
    Anesthesiology; 2021 Feb; 134(2):350-351. PubMed ID: 33433614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.